Genexine, Inc. (095700.KQ)

KRW 5590.0

(-3.79%)

Net Income Summary of Genexine, Inc.

Genexine, Inc.'s latest annual net income in 2023 was -66.87 Billion KRW , down -18.83% from previous year.
Genexine, Inc.'s latest quarterly net income in 2024 Q2 was -12.09 Billion KRW , down -4.54% from previous quarter.
Genexine, Inc. reported an annual net income of -56.27 Billion KRW in 2022, down -17.91% from previous year.
Genexine, Inc. reported an annual net income of -47.72 Billion KRW in 2021, down -273.11% from previous year.
Genexine, Inc. reported a quarterly net income of -11.56 Billion KRW for 2024 Q1, down -546.61% from previous quarter.
Genexine, Inc. reported a quarterly net income of -24.61 Billion KRW for 2023 Q2, down -2.93% from previous quarter.

Annual Net Income Chart of Genexine, Inc. (2023 - 2012)

Historical Annual Net Income of Genexine, Inc. (2023 - 2012)

Year	Net Income	Net Income Growth
2023	-66.87 Billion KRW	-18.83%
2022	-56.27 Billion KRW	-17.91%
2021	-47.72 Billion KRW	-273.11%
2020	27.56 Billion KRW	267.0%
2019	-16.5 Billion KRW	51.54%
2018	-34.06 Billion KRW	-76.24%
2017	-19.32 Billion KRW	37.51%
2016	-30.93 Billion KRW	-2068.17%
2015	-1.42 Billion KRW	0.0%
2012	-2.09 Billion KRW	0.0%

Year	Net Income	Net Income Growth
2024 Q2	-12.09 Billion KRW	-4.54%
2024 Q1	-11.56 Billion KRW	-546.61%
2023 Q2	-24.61 Billion KRW	-2.93%
2023 FY	-66.87 Billion KRW	-18.83%
2023 Q4	2.58 Billion KRW	112.37%
2023 Q3	-20.93 Billion KRW	14.95%
2023 Q1	-23.91 Billion KRW	38.15%
2022 Q4	-38.66 Billion KRW	-105.79%
2022 FY	-56.27 Billion KRW	-17.91%
2022 Q1	16.39 Billion KRW	150.25%
2022 Q3	-18.78 Billion KRW	-23.45%
2022 Q2	-15.22 Billion KRW	-192.81%
2021 Q1	21.31 Billion KRW	35.96%
2021 FY	-47.72 Billion KRW	-273.11%
2021 Q2	-20.1 Billion KRW	-194.32%
2021 Q3	-16.3 Billion KRW	18.9%
2021 Q4	-32.63 Billion KRW	-100.15%
2020 Q3	34.35 Billion KRW	556.28%
2020 FY	27.56 Billion KRW	267.0%
2020 Q2	-7.52 Billion KRW	49.58%
2020 Q4	15.67 Billion KRW	-54.36%
2020 Q1	-14.93 Billion KRW	6.14%
2019 Q2	-21.43 Billion KRW	-171.95%
2019 FY	-16.5 Billion KRW	51.54%
2019 Q4	-15.9 Billion KRW	-77.63%
2019 Q3	-8.95 Billion KRW	58.22%
2019 Q1	29.78 Billion KRW	0.0%
2018 FY	-34.06 Billion KRW	-76.24%
2017 FY	-19.32 Billion KRW	37.51%
2016 FY	-30.93 Billion KRW	-2068.17%
2015 FY	-1.42 Billion KRW	0.0%
2013 Q3	-1.71 Billion KRW	0.0%
2012 Q3	-417.21 Million KRW	0.0%
2012 FY	-2.09 Billion KRW	0.0%

Peer Net Income Comparison of Genexine, Inc.

Name	Net Income	Net Income Difference
HLB Co., Ltd.	-189.07 Billion KRW	64.632%
iNtRON Biotechnology, Inc.	-9.69 Billion KRW	-589.744%
BINEX Co., Ltd.	4.67 Billion KRW	1531.752%
Bioneer Corporation	-10.58 Billion KRW	-531.655%
Anterogen.Co.,Ltd.	-2.84 Billion KRW	-2253.997%
MEDIPOST Co., Ltd.	5.83 Billion KRW	1245.095%
CrystalGenomics, Inc.	-48.92 Billion KRW	-36.69%
Helixmith Co., Ltd	-64.08 Billion KRW	-4.346%
Chabiotech Co.,Ltd.	-8.43 Billion KRW	-693.163%
Medy-Tox Inc.	9.75 Billion KRW	785.524%
Peptron, Inc.	-15.92 Billion KRW	-320.01%
Amicogen, Inc.	-23.28 Billion KRW	-187.147%
HLB Therapeutics Co.,Ltd.	-2.3 Billion KRW	-2804.818%
LegoChem Biosciences, Inc.	-73.7 Billion KRW	9.267%
ALTEOGEN Inc.	-3.37 Billion KRW	-1883.339%
PharmaResearch Co., Ltd.	76.55 Billion KRW	187.358%
SillaJen, Inc.	-20.36 Billion KRW	-228.306%
JETEMA, Co., Ltd.	13.96 Billion KRW	578.834%
OliX Pharmaceuticals,Inc	-19.1 Billion KRW	-250.092%
Genomictree Inc.	-8.75 Billion KRW	-663.742%
MedPacto, Inc.	-35.32 Billion KRW	-89.31%
D&D Pharmatech	3.93 Billion KRW	1799.971%
EASY BIO,Inc.	15.54 Billion KRW	530.227%
GI Innovation, Inc.	-55.49 Billion KRW	-20.503%